Healthcare use and costs of medium-chain acyl-coa dehydrogenase deficiency in Australia: Screening versus no screening

UTSePress Research/Manakin Repository

Search UTSePress Research

Advanced Search


My Account

Show simple item record Haas, Marion en_US Chaplin, Meredyth en_US Joy, Pamela en_US Wiley, V en_US Black, C en_US Wilcken, B en_US 2009-12-21T02:34:27Z 2009-12-21T02:34:27Z 2007 en_US
dc.identifier 2006012713 en_US
dc.identifier.citation Haas Marion et al. 2007, 'Healthcare use and costs of medium-chain acyl-coa dehydrogenase deficiency in Australia: Screening versus no screening', Mosby Inc, vol. 151, no. 2, pp. 121-126. en_US
dc.identifier.issn 0022-3476 en_US
dc.identifier.other C1 en_US
dc.description.abstract Objective To describe and analyze the use and costs of hospital services for children diagnosed with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency either with newborn screening or clinical diagnosis in Australia between 1994 and 2002. MCAD deficiency is a potentially lethal disorder of fatty-acid oxidation. Study design We conducted a retrospective audit of medical records supplemented by a parental survey. Results A total of 59 children with MCAD deficiency were identified, 24 by using newborn screening. In the first 4 years of life, screening children cost an average of $A1676 (US$1297) per year for inpatient, emergency department, and outpatient visits, compared with $A1796 (US$1390) for children in whom a clinical diagnosis was made. Forty-two percent of the children who underwent screening were admitted to the hospital, compared with 71% of children who did not undergo screening. Children who did not undergo screening used significantly more inpatient services and cost significantly more in emergency services. There were also some significant differences in use on a year-by-year basis. Conclusions Children who do not undergo screening may be more likely to be admitted to the hospital and to incur higher emergency department costs than children who underwent screening, and children seem more likely to attend hospital outpatient clinics. Screening does not result in higher costs from a hospital perspective. en_US
dc.publisher Mosby Inc en_US
dc.relation.hasversion Accepted manuscript version
dc.relation.isbasedon en_US
dc.rights NOTICE: this is the author’s version of a work that was accepted for publication in The Journal of Pediatrics. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in The Journal of Pediatrics, [VOL 151, ISSUE 2, August 2007 , ,
dc.title Healthcare use and costs of medium-chain acyl-coa dehydrogenase deficiency in Australia: Screening versus no screening en_US
dc.parent Journal of Pediatrics en_US
dc.journal.volume 151 en_US
dc.journal.number 2 en_US
dc.publocation St Louis, USA en_US
dc.identifier.startpage 121 en_US
dc.identifier.endpage 126 en_US BUS.Centre for Health Economics Research and Evaluation en_US
dc.conference Verified OK en_US
dc.for 111400 en_US
dc.personcode 020119 en_US
dc.personcode 0000022431 en_US
dc.personcode 0000032652 en_US
dc.personcode 0000032653 en_US
dc.personcode 0000032655 en_US
dc.personcode 0000032651 en_US
dc.percentage 100 en_US Paediatrics and Reproductive Medicine en_US
dc.classification.type FOR-08 en_US
dc.description.keywords Newborn Screening, costs, Australia en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record